OBJECTIVE: Positive associations between polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) and the pathogenesis of schizophrenia as well as response to antipsychotic treatment have been reported. The objective of this study was to determine whether refractory psychiatric symptoms in antipsychotic non-responders are related to polymorphisms in GRM3. METHODS: Ninety-five treatment refractory schizophrenia participants were enrolled. Prior to a medication switch, global psychopathology and negative symptoms were rated. These participants were genotyped for seven markers in GRM3. Genotype associations with symptoms were assessed. RESULTS: Two markers in GRM3 (rs1989796 and rs1476455), were associated with the presence of refractory global symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) Total scores. Participants with an rs1476455_CC genotype had significantly higher BPRS scores than A-carriers (55.1±10.4 vs. 48.3±9.2; F=7.6, p=0.0071). Additionally, participants with the rs1989796_CC genotype had significantly higher BPRS scores than T-carriers (50.1±5.7 vs. 55.8±10.5, F=7.1, p=0.0091). No evidence for significant associations with negative symptoms was observed. CONCLUSIONS: Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in persons with schizophrenia.
OBJECTIVE: Positive associations between polymorphisms in the type-three metabotropic glutamate receptor gene (GRM3) and the pathogenesis of schizophrenia as well as response to antipsychotic treatment have been reported. The objective of this study was to determine whether refractory psychiatric symptoms in antipsychotic non-responders are related to polymorphisms in GRM3. METHODS: Ninety-five treatment refractory schizophreniaparticipants were enrolled. Prior to a medication switch, global psychopathology and negative symptoms were rated. These participants were genotyped for seven markers in GRM3. Genotype associations with symptoms were assessed. RESULTS: Two markers in GRM3 (rs1989796 and rs1476455), were associated with the presence of refractory global symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) Total scores. Participants with an rs1476455_CC genotype had significantly higher BPRS scores than A-carriers (55.1±10.4 vs. 48.3±9.2; F=7.6, p=0.0071). Additionally, participants with the rs1989796_CC genotype had significantly higher BPRS scores than T-carriers (50.1±5.7 vs. 55.8±10.5, F=7.1, p=0.0091). No evidence for significant associations with negative symptoms was observed. CONCLUSIONS: Polymorphisms in the GRM3 gene may be associated with refractory global psychosis symptoms but not negative symptoms in persons with schizophrenia.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: M Daniele Fallin; Virginia K Lasseter; Dimitrios Avramopoulos; Kristin K Nicodemus; Paula S Wolyniec; John A McGrath; Gary Steel; Gerald Nestadt; Kung-Yee Liang; Richard L Huganir; David Valle; Ann E Pulver Journal: Am J Hum Genet Date: 2005-10-28 Impact factor: 11.025
Authors: Kristin K Nicodemus; Bhaskar S Kolachana; Radhakrishna Vakkalanka; Richard E Straub; Ina Giegling; Michael F Egan; Dan Rujescu; Daniel R Weinberger Journal: Hum Genet Date: 2006-09-28 Impact factor: 4.132
Authors: Hao-Yang Tan; Qiang Chen; Steven Sust; Joshua W Buckholtz; John D Meyers; Michael F Egan; Venkata S Mattay; Andreas Meyer-Lindenberg; Daniel R Weinberger; Joseph H Callicott Journal: Proc Natl Acad Sci U S A Date: 2007-07-16 Impact factor: 11.205
Authors: Nadine Norton; Hywel J Williams; Sarah Dwyer; Dobril Ivanov; Anna C Preece; Amy Gerrish; Nigel M Williams; Pamela Yerassimou; Stanley Zammit; Michael C O'Donovan; Michael J Owen Journal: BMC Psychiatry Date: 2005-05-13 Impact factor: 3.630
Authors: Rebekka Lencer; Jeffrey R Bishop; Margret S H Harris; James L Reilly; Shitalben Patel; Rick Kittles; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-10-25 Impact factor: 5.270
Authors: J M Stevenson; J L Reilly; M S H Harris; S R Patel; P J Weiden; K M Prasad; J A Badner; V L Nimgaonkar; M S Keshavan; J A Sweeney; J R Bishop Journal: Transl Psychiatry Date: 2016-02-23 Impact factor: 6.222
Authors: S M Saini; S G Mancuso; Md S Mostaid; C Liu; C Pantelis; I P Everall; C A Bousman Journal: Transl Psychiatry Date: 2017-08-08 Impact factor: 6.222
Authors: L E Jin; M Wang; S-T Yang; Y Yang; V C Galvin; T C Lightbourne; D Ottenheimer; Q Zhong; J Stein; A Raja; C D Paspalas; A F T Arnsten Journal: Mol Psychiatry Date: 2016-08-09 Impact factor: 15.992